Ocular Surgery News
Results from a 24 week placebo-controlled phase 3 study recently released by OphthaliX showed that the company’s licensed drug, CF101, for the treatment of dry eye, while well-tolerated, met neither primary nor secondary efficacy endpoints, according to a company press release.